Totally implanted venous access-associated adverse events in oncology: Results from a prospective 1-year surveillance programme.

[1]  J. Muir,et al.  Morbidity-mortality conference for adverse events associated with totally implanted venous access for cancer chemotherapy , 2016, Supportive Care in Cancer.

[2]  C. Ferreccio,et al.  Heart Failure in Rural Communities. , 2015, Heart failure clinics.

[3]  T. Seo,et al.  Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports , 2014, Korean journal of radiology.

[4]  Ethan A. Halm,et al.  Impact of Social Factors on Risk of Readmission or Mortality in Pneumonia and Heart Failure: Systematic Review , 2013, Journal of General Internal Medicine.

[5]  P. Vanhems,et al.  Totally implantable central venous access port infections in patients with digestive cancer: incidence and risk factors. , 2012, American journal of infection control.

[6]  P. Cassier,et al.  Infections associées aux chambres à cathéter implantables, épidémiologie et prévention : revue de la littérature , 2012 .

[7]  S. Ahn,et al.  Ultrasound and Fluoroscopy-Guided Placement of Central Venous Ports via Internal Jugular Vein: Retrospective Analysis of 1254 Port Implantations at a Single Center , 2012, Korean journal of radiology.

[8]  L. Rasero,et al.  The late complications of totally implantable central venous access ports: the results from an Italian multicenter prospective observation study. , 2011, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[9]  J. Yoshida,et al.  Association between risk of bloodstream infection and duration of use of totally implantable access ports and central lines: a 24-month study. , 2011, American journal of infection control.

[10]  G. Quéré,et al.  [Percutaneous implantable port-related infection and thrombosis: diagnostic and management]. , 2011, Bulletin du cancer.

[11]  A. Lefort,et al.  Complications infectieuses liées aux chambres implantables : caractéristiques et prise en charge , 2010 .

[12]  C. Heibl,et al.  Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis. , 2010, European journal of cancer care.

[13]  M. Prins,et al.  Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. , 2010, Thrombosis research.

[14]  N. Wolosker,et al.  Totally Implantable Ports Connected to Valved Catheters for Chemotherapy: Experience from 350 Groshong Devices , 2010 .

[15]  D. Lebeaux,et al.  [Totally implanted access port-related infections: features and management]. , 2010, La Revue de medecine interne.

[16]  Ming-Shian Lu,et al.  Analysis of risk factors for central venous port failure in cancer patients. , 2009, World journal of gastroenterology.

[17]  J. Favre,et al.  Incidence, prévalence et facteurs de risque de survenue d’une première complication infectieuse sur chambres à cathéter implantables , 2009 .

[18]  C. Righini,et al.  Complications d'un dispositif intraveineux implantable pour chimiothérapie dans les cancers des voies aérodigestives supérieures , 2009 .

[19]  F. Rosendaal,et al.  Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Hochhauser,et al.  A comparison of Hickman line- and Port-a-Cath-associated complications in patients with solid tumours undergoing chemotherapy. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[21]  A. Loh,et al.  Port-A-Cath insertions in acute leukemia: does thrombocytopenia affect morbidity? , 2007, Journal of pediatric surgery.

[22]  S. Boutreux,et al.  Social determinants of access to reference care centres for patients with colorectal cancer--a multilevel analysis. , 2006, European journal of cancer.

[23]  Dan M. Kluger,et al.  The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. , 2006, Mayo Clinic proceedings.

[24]  M. Levine,et al.  Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Rubie,et al.  Utilisation des sites veineux implantables dans les chimiothérapies massives en pédiatrie , 2006 .

[26]  S. Boutreux,et al.  Social and geographic disparities in access to reference care site for patients with colorectal cancer in France , 2005, British Journal of Cancer.

[27]  B. Asselain,et al.  Thrombose symptomatique sur cathéter veineux central de longue durée en oncologie : un score de risque prédictif? , 2005 .

[28]  F. Rosendaal,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[29]  J. Petit,et al.  Cathéters à chambre implantable : épidémiologie des complications et étude microbiologique des dispositifs après ablation , 2004 .

[30]  P. Saip,et al.  Totally implantable venous-access ports: local problems and extravasation injury. , 2002, The Lancet. Oncology.

[31]  D. Maki,et al.  The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  A. Macrez,et al.  Long-Term Central Venous Catheter Infection in HIV-infected and Cancer Patients: A Multicenter Cohort Study , 1999, Infection Control & Hospital Epidemiology.